Clinical trial NCT01186783 - References

Multiple Organ Dysfunction Syndrome — Reducing Elevated Heart Rate in Patients With Multiple Organ Dysfunction Syndrome (MODS) by Ivabradine

Citation(s)

•   American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis
  Crit Care Med. 1992 Jun;20(6):864-74. Review.
•   Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr; Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group
  Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001 Mar 8;344(10):699-709.
•   Bernardin G, Strosberg AD, Bernard A, Mattei M, Marullo S
  Beta-adrenergic receptor-dependent and -independent stimulation of adenylate cyclase is impaired during severe sepsis in humans. Intensive Care Med. 1998 Dec;24(12):1315-22.
•   Borer JS
  Drug insight: If inhibitors as specific heart-rate-reducing agents. Nat Clin Pract Cardiovasc Med. 2004 Dec;1(2):103-9. Review. Erratum in: Nat Clin Pract Cardiovasc Med. 2006 Apr;3(4):231.
•   Cooney MT, Vartiainen E, Laatikainen T, Juolevi A, Dudina A, Graham IM
  Elevated resting heart rate is an independent risk factor for cardiovascular disease in healthy men and women. Am Heart J. 2010 Apr;159(4):612-619.e3. doi: 10.1016/j.ahj.2009.12.029. Erratum in: Am Heart J. 2010 Jul;160(1):208. Laakitainen, Tinna [corrected to Laatikainen, Tiina].
•   Cucherat M
  Quantitative relationship between resting heart rate reduction and magnitude of clinical benefits in post-myocardial infarction: a meta-regression of randomized clinical trials. Eur Heart J. 2007 Dec;28(24):3012-9. Epub 2007 Nov 2. Review.
•   Heidland UE, Strauer BE
  Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. Circulation. 2001 Sep 25;104(13):1477-82.
•   Hennen R, Friedrich I, Hoyer D, Nuding S, Rauchhaus M, Schulze M, Schlisske S, Schwesig R, Schlitt A, Buerke M, Müller-Werdan U, Werdan K, Schmidt H
  [Autonomic dysfunction and beta-adrenergic blockers in multiple organ dysfunction syndrome]. Dtsch Med Wochenschr. 2008 Nov;133(48):2500-4. doi: 10.1055/s-0028-1100944. Epub 2008 Nov 19. German.
•   Herndon DN, Barrow RE, Rutan TC, Minifee P, Jahoor F, Wolfe RR
  Effect of propranolol administration on hemodynamic and metabolic responses of burned pediatric patients. Ann Surg. 1988 Oct;208(4):484-92.
•   Herndon DN, Hart DW, Wolf SE, Chinkes DL, Wolfe RR
  Reversal of catabolism by beta-blockade after severe burns. N Engl J Med. 2001 Oct 25;345(17):1223-9.
•   Kjekshus J
  Heart rate reduction--a mechanism of benefit? Eur Heart J. 1987 Dec;8 Suppl L:115-22. Review.
•   Kjekshus JK
  Importance of heart rate in determining beta-blocker efficacy in acute and long-term acute myocardial infarction intervention trials. Am J Cardiol. 1986 Apr 25;57(12):43F-49F.
•   Knaus WA, Draper EA, Wagner DP, Zimmerman JE
  APACHE II: a severity of disease classification system. Crit Care Med. 1985 Oct;13(10):818-29.
•   Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G; International Sepsis Definitions Conference
  2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med. 2003 Apr;29(4):530-8. Epub 2003 Mar 28. Review.
•   Manz M, Reuter M, Lauck G, Omran H, Jung W
  A single intravenous dose of ivabradine, a novel I(f) inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction. Cardiology. 2003;100(3):149-55.
•   Marshall JC, Cook DJ, Christou NV, Bernard GR, Sprung CL, Sibbald WJ
  Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med. 1995 Oct;23(10):1638-52. Review.
•   Muller-Werdan U, Buerke M, Ebelt H, Heinroth KM, Herklotz A, Loppnow H, Ruß M, Schlegel F, Schlitt A, Schmidt HB, Söffker G, Werdan K
  Septic cardiomyopathy - A not yet discovered cardiomyopathy? Exp Clin Cardiol. 2006 Fall;11(3):226-36.
•   Norbury WB, Jeschke MG, Herndon DN
  Metabolism modulators in sepsis: propranolol. Crit Care Med. 2007 Sep;35(9 Suppl):S616-20. Review.
•   Opal S, Laterre PF, Abraham E, Francois B, Wittebole X, Lowry S, Dhainaut JF, Warren B, Dugernier T, Lopez A, Sanchez M, Demeyer I, Jauregui L, Lorente JA, McGee W, Reinhart K, Kljucar S, Souza S, Pribble J; Controlled Mortality Trial of Platelet-Activating Factor Acetylhydrolase in Severe Sepsis Investigators
  Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis: results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial. Crit Care Med. 2004 Feb;32(2):332-41.
•   Palatini P, Julius S
  Association of tachycardia with morbidity and mortality: pathophysiological considerations. J Hum Hypertens. 1997 Aug;11 Suppl 1:S19-27. Review.
•   Pilz G, Appel R, Kreuzer E, Werdan K
  Comparison of early IgM-enriched immunoglobulin vs polyvalent IgG administration in score-identified postcardiac surgical patients at high risk for sepsis. Chest. 1997 Feb;111(2):419-26.
•   Pilz G, Kääb S, Kreuzer E, Werdan K
  Evaluation of definitions and parameters for sepsis assessment in patients after cardiac surgery. Infection. 1994 Jan-Feb;22(1):8-17.
•   Pilz G, Werdan K
  Cardiovascular parameters and scoring systems in the evaluation of response to therapy in sepsis and septic shock. Infection. 1990 Sep-Oct;18(5):253-62.
•   Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M; Early Goal-Directed Therapy Collaborative Group
  Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001 Nov 8;345(19):1368-77.
•   Schmidt H, Müller-Werdan U, Hoffmann T, Francis DP, Piepoli MF, Rauchhaus M, Prondzinsky R, Loppnow H, Buerke M, Hoyer D, Werdan K
  Autonomic dysfunction predicts mortality in patients with multiple organ dysfunction syndrome of different age groups. Crit Care Med. 2005 Sep;33(9):1994-2002.
•   Schmidt HB, Werdan K, Müller-Werdan U
  Autonomic dysfunction in the ICU patient. Curr Opin Crit Care. 2001 Oct;7(5):314-22. Review.
•   Thollon C, Cambarrat C, Vian J, Prost JF, Peglion JL, Vilaine JP
  Electrophysiological effects of S 16257, a novel sino-atrial node modulator, on rabbit and guinea-pig cardiac preparations: comparison with UL-FS 49. Br J Pharmacol. 1994 May;112(1):37-42.
•   Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome
  The Acute Respiratory Distress Syndrome Network. N Engl J Med. 2000 May 4;342(18):1301-8.
•   Vincent JL, Angus DC, Artigas A, Kalil A, Basson BR, Jamal HH, Johnson G 3rd, Bernard GR; Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) Study Group
  Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial. Crit Care Med. 2003 Mar;31(3):834-40.
•   Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, Reinhart CK, Suter PM, Thijs LG
  The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996 Jul;22(7):707-10.
•   Werdan K, Pilz G, Bujdoso O, Fraunberger P, Neeser G, Schmieder RE, Viell B, Marget W, Seewald M, Walger P, Stuttmann R, Speichermann N, Peckelsen C, Kurowski V, Osterhues HH, Verner L, Neumann R, Müller-Werdan U; Score-Based Immunoglobulin Therapy of Sepsis (SBITS) Study Group
  Score-based immunoglobulin G therapy of patients with sepsis: the SBITS study. Crit Care Med. 2007 Dec;35(12):2693-2701.
•   Werdan K, Schmidt H, Ebelt H, Zorn-Pauly K, Koidl B, Hoke RS, Heinroth K, Müller-Werdan U
  Impaired regulation of cardiac function in sepsis, SIRS, and MODS. Can J Physiol Pharmacol. 2009 Apr;87(4):266-74. doi: 10.1139/Y09-012. Review.
•   Wilhelmsen L, Berglund G, Elmfeldt D, Tibblin G, Wedel H, Pennert K, Vedin A, Wilhelmsson C, Werkö L
  The multifactor primary prevention trial in Göteborg, Sweden. Eur Heart J. 1986 Apr;7(4):279-88.
•   Zorn-Pauly K, Pelzmann B, Lang P, Mächler H, Schmidt H, Ebelt H, Werdan K, Koidl B, Müller-Werdan U
  Endotoxin impairs the human pacemaker current If. Shock. 2007 Dec;28(6):655-661.
•   Zuppa AF, Nadkarni V, Davis L, Adamson PC, Helfaer MA, Elliott MR, Abrams J, Durbin D
  The effect of a thyroid hormone infusion on vasopressor support in critically ill children with cessation of neurologic function. Crit Care Med. 2004 Nov;32(11):2318-22.

Reducing Elevated Heart Rate in Patients With Multiple Organ Dysfunction Syndrome (MODS) by the "Funny Channel" Current (If) Inhibitor Ivabradine

Details for clinical trial NCT01186783